Tag: Merck
Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skippin

Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skippin

- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications ...

Lees verder
Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with

Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with

ASCO Abstract # Tepotinib (MET kinase inhibitor): 9005 Not intended for UK- , Canada- or US-based media DARMSTADT, Germany, June 3, 2019 /PRNewswire/ -- -- ...

Lees verder
Merck Data at ASCO 2019 Showcase Multiple Innovative Molecules with Potential to Impact Unmet Needs in Cancer Care

Merck Data at ASCO 2019 Showcase Multiple Innovative Molecules with Potential to Impact Unmet Needs in Cancer Care

DARMSTADT, Germany, May 15, 2019 /PRNewswire/ -- Not intended for UK- , Canada- or US-based media ASCO Abstract # Bintrafusp alfa (bifunctional fusion protein): TPS9114; ...

Lees verder
Merck Receives First U.S. Patent for Improved CRISPR Genome-Editing Method

Merck Receives First U.S. Patent for Improved CRISPR Genome-Editing Method

- Proxy-CRISPR technology provides solution to improve genome editing and advance new possibilities for research - Helps modify difficult-to-access regions of the genome, ...

Lees verder
Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer

Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer

DARMSTADT, Germany and NEW YORK, December 21, 2018 /PRNewswire/ -- Not intended for US, Canada and UK-based media   Merck and Pfizer Inc. today announced that data from a ...

Lees verder
Merck Announces EMA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

Merck Announces EMA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

DARMSTADT, Germany, December 20, 2018 /PRNewswire/ -- The information contained is not intended for distribution in the USA, Canada or the UK    - European Medicine ...

Lees verder
Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

DARMSTADT, Germany and NEW YORK, November 19, 2018 /PRNewswire/ -- Not intended for US, Canada and UK-based media  Merck and Pfizer Inc. today announced that the Phase III ...

Lees verder
Merck Presents Updated Results for Bifunctional Immunotherapy M7824 at ESMO 2018 Congress

Merck Presents Updated Results for Bifunctional Immunotherapy M7824 at ESMO 2018 Congress

DARMSTADT, Germany, October 22, 2018 /PRNewswire/ -- The information contained is not intended for distribution in the USA, Canada or the UK  ESMO Abstract # M7824 (TGF ...

Lees verder
Merck Awarded Australian CRISPR Nickase Patent for Foundational Genome-Editing Technology

Merck Awarded Australian CRISPR Nickase Patent for Foundational Genome-Editing Technology

- Patent covers paired Cas9 nickase technology to reduce off-target effects, advance gene therapy and research - Expands company's foundational CRISPR cutting and integration ...

Lees verder
Merck Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018

Merck Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018

DARMSTADT, Germany, June 3, 2018 /PRNewswire/ -- ASCO Abstract # Tepotinib (c-Met kinase inhibitor): 9082, 9016; M7824 (TGF-ss trap/anti-PD-L1): 3007, 9017, 2566; M2698 (dual ...

Lees verder
BizPress.nl